study_id,first_author,year,title,journal,study_type,total_participants,n_patients,n_controls,age_range,conditions,quality_score,biomarkers,total_studies
LIN2020_META,Lin Y,2020,Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders: A meta-analysis,Annals of Clinical and Translational Neurology,Meta-analysis,1563,718.0,845,Mixed pediatric and adult,Mixed mitochondrial diseases,9.5,"[{'name': 'FGF-21', 'n_studies': 5, 'n_participants': 718, 'biomaterial': 'Serum', 'analytical_method': 'ELISA', 'sensitivity': 71.0, 'sensitivity_ci': [53.0, 84.0], 'specificity': 88.0, 'specificity_ci': [82.0, 93.0], 'auc': 0.9, 'auc_ci': [0.87, 0.92], 'dor': 18.0, 'dor_ci': [6.0, 54.0], 'lr_positive': 6.1, 'lr_negative': 0.33, 'heterogeneity_i2': 'Not reported'}, {'name': 'GDF-15', 'n_studies': 7, 'n_participants': 845, 'biomaterial': 'Serum', 'analytical_method': 'ELISA', 'sensitivity': 83.0, 'sensitivity_ci': [65.0, 92.0], 'specificity': 92.0, 'specificity_ci': [84.0, 96.0], 'auc': 0.94, 'auc_ci': [0.92, 0.96], 'dor': 52.0, 'dor_ci': [13.0, 205.0], 'lr_positive': 9.9, 'lr_negative': 0.19, 'heterogeneity_i2': 'Not reported'}]",
MARESCA2020,Maresca A,2020,Expanding and validating the biomarkers for mitochondrial diseases,Journal of Molecular Medicine,Prospective cohort,123,123.0,Not specified,Mixed pediatric and adult,"MELAS, MERRF, LHON, CPEO, other mitochondrial diseases",8.5,"[{'name': 'ccf-mtDNA', 'biomaterial': 'Plasma', 'analytical_method': 'qPCR', 'condition_specific': 'MELAS', 'auc_melas': 0.73, 'auc_ci': [0.6, 0.86], 'p_value': '<0.01', 'fold_change': 'Significantly elevated', 'clinical_utility': 'Monitoring acute events'}, {'name': 'FGF-21', 'biomaterial': 'Serum', 'analytical_method': 'ELISA', 'condition_specific': 'MELAS, MERRF', 'significance': 'p<0.001', 'fold_change': 'Significantly elevated'}, {'name': 'GDF-15', 'biomaterial': 'Serum', 'analytical_method': 'ELISA', 'condition_specific': 'MELAS, MERRF', 'significance': 'p<0.001', 'fold_change': 'Significantly elevated'}, {'name': 'Creatine', 'biomaterial': 'Serum', 'analytical_method': 'Enzymatic assay', 'condition_specific': 'Non-specific', 'significance': 'p<0.05', 'fold_change': 'Moderately elevated'}]",
SHAYOTA2024_REVIEW,Shayota BJ,2024,Biomarkers of mitochondrial disorders,Neurotherapeutics,Systematic review,1139,,,,,,"[{'name': 'Lactate', 'n_studies': 27, 'n_blood_samples': 935, 'n_csf_samples': 204, 'biomaterial': 'Blood, CSF', 'analytical_method': 'Various enzymatic methods', 'sensitivity_range': [15.1, 100.0], 'specificity_range': [83.0, 100.0], 'significant_studies': 13, 'non_significant_studies': 5, 'melas_specific_studies': 6, 'exercise_dependent': True}, {'name': 'GDF-15', 'n_studies': 17, 'n_cohorts': 20, 'n_blood_samples': 785, 'n_csf_samples': 16, 'biomaterial': 'Blood, CSF', 'analytical_method': 'ELISA', 'auc_range': [0.69, 0.99], 'sensitivity_range': [66.0, 97.9], 'specificity_range': [64.0, 97.0], 'significant_studies': 14}, {'name': 'FGF-21', 'n_studies': 22, 'n_cohorts': 25, 'n_blood_samples': 1217, 'biomaterial': 'Blood', 'analytical_method': 'ELISA', 'auc_range': [0.75, 0.97], 'sensitivity_range': [20.0, 82.8], 'specificity_range': [57.5, 97.2], 'significant_studies': 18, 'cutoff_range': [200, 1947], 'standardization_needed': True}]",27.0
SUOMALAINEN2011,Suomalainen A,2011,FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies,The Lancet Neurology,Case-control,134,67.0,67,Adult (mean 45Â±16 years),Muscle-manifesting mitochondrial diseases,8.0,"[{'name': 'FGF-21', 'biomaterial': 'Serum', 'analytical_method': 'ELISA', 'cutoff': 350, 'sensitivity': 65.7, 'specificity': 100.0, 'auc': 0.85, 'p_value': '<0.001', 'fold_change': 5.1, 'median_patients': 523, 'median_controls': 102}]",
MONTERO2016,Montero R,2016,GDF-15 is elevated in children with mitochondrial diseases,PLoS One,Case-control,102,51.0,51,Pediatric (0.1-17.9 years),Various mitochondrial diseases,7.5,"[{'name': 'GDF-15', 'biomaterial': 'Serum', 'analytical_method': 'ELISA', 'cutoff': 1200, 'sensitivity': 70.6, 'specificity': 86.3, 'auc': 0.82, 'p_value': '<0.001', 'median_patients': 1891, 'median_controls': 444}]",
YATSUGA2015,Yatsuga S,2015,Growth differentiation factor-15 as a useful biomarker for mitochondrial disorders,Annals of Neurology,Case-control,196,96.0,100,Mixed (1-78 years),Various mitochondrial diseases,8.5,"[{'name': 'GDF-15', 'biomaterial': 'Serum', 'analytical_method': 'ELISA', 'cutoff': 1800, 'sensitivity': 74.0, 'specificity': 90.0, 'auc': 0.89, 'p_value': '<0.001', 'median_patients': 2850, 'median_controls': 550}, {'name': 'FGF-21', 'biomaterial': 'Serum', 'analytical_method': 'ELISA', 'cutoff': 200, 'sensitivity': 72.9, 'specificity': 85.0, 'auc': 0.84, 'p_value': '<0.001', 'median_patients': 389, 'median_controls': 89}]",
DAVIS2013,Davis RL,2013,Serum FGF-21 levels are elevated in association with mitochondrial disease,PLoS One,Case-control,159,76.0,83,Mixed pediatric and adult,Various mitochondrial diseases,7.0,"[{'name': 'FGF-21', 'biomaterial': 'Serum', 'analytical_method': 'ELISA', 'cutoff': 350, 'sensitivity': 68.4, 'specificity': 84.3, 'auc': 0.81, 'p_value': '<0.001'}, {'name': 'Lactate', 'biomaterial': 'Serum', 'analytical_method': 'Enzymatic', 'cutoff': 2.2, 'sensitivity': 30.3, 'specificity': 95.2, 'auc': 0.63, 'p_value': '<0.05'}, {'name': 'Creatine kinase', 'biomaterial': 'Serum', 'analytical_method': 'Enzymatic', 'sensitivity': 25.0, 'specificity': 90.4, 'auc': 0.58, 'p_value': 'NS'}]",
KOENE2014,Koene S,2014,Serum GDF15 levels correlate to mitochondrial disease severity,Neurology,Case-control,140,70.0,70,Adult (18-75 years),Various mitochondrial diseases,8.0,"[{'name': 'GDF-15', 'biomaterial': 'Serum', 'analytical_method': 'ELISA', 'cutoff': 1200, 'sensitivity': 80.0, 'specificity': 85.7, 'auc': 0.88, 'p_value': '<0.001', 'correlation_severity': 'r=0.65, p<0.001'}]",
